Skip to main content
Back
Watch Compare

LISATA THERAPEUTICS, INC.

Data quality: 100%
LSTA
Nasdaq Manufacturing Chemicals
$5.01
▲ $0.01 (0.10%)
Mkt Cap: 45.21 M
Price
$5.01
Mkt Cap
45.21 M
Day Range
$5.00 — $5.01
52-Week Range
$1.81 — $5.07
Volume
10,505
Open $5.00
50D / 200D Avg
$4.68
6.96% above
50D / 200D Avg
$2.95
69.51% above

Quick Summary

Key Takeaways

Negative free cash flow of -17.26 M
Capital efficient — spends only 2.62% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-95.01%
Below sector avg (-53.41%)
ROIC-83.40%
Net Margin-1704.86%
Op. Margin-1876.54%

Safety

Debt / Equity
N/A
Current Ratio4.72
Interest CoverageN/A

Valuation

PE (TTM)
-2.48
Below sector avg (-1.48)
P/B Ratio2.60
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.5 -1.5
P/B 2.6 1.6
ROE % -95.0 -53.4
Net Margin % -1704.9 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.07 M Net Income (TTM) -18.24 M
ROE -95.01% ROA -77.76%
Gross Margin N/A Operating Margin -1876.54%
Net Margin -1704.86% Free Cash Flow (TTM) -17.26 M
ROIC -83.40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.72
Interest Coverage N/A Asset Turnover 0.05
Working Capital 17.01 M Tangible Book Value 16.97 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.48 Forward P/E N/A
P/B Ratio 2.60 P/S Ratio 42.25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -38.17%
Market Cap 45.21 M Enterprise Value 26.21 M
Per Share
EPS (Diluted TTM) -2.13 Revenue / Share 0.12
FCF / Share -1.91 OCF / Share -1.91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2.62% FCF Conversion 94.59%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.00 M 0.0 — — —
Net Income -19.99 M -20.84 M -54.23 M -27.47 M -8.15 M
EPS (Diluted) -2.40 -2.58 -10.47 -0.50 —
Gross Profit — — — — —
Operating Income -22.41 M -25.71 M -57.60 M -29.05 M -19.15 M
EBITDA — — — — —
R&D Expenses — — — 17.68 M 9.25 M
SG&A Expenses — 12.97 M 14.14 M 11.37 M 9.89 M
D&A 174,000.0 189,000.0 69,000.0 55,000.0 100,000.0
Interest Expense — — — — —
Income Tax -798,000.0 -2.33 M -2.48 M -1.51 M -10.87 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 35.00 M 54.69 M 73.03 M 97.01 M 36.00 M
Total Liabilities 5.69 M 6.80 M 6.71 M 5.01 M 3.76 M
Shareholders' Equity 29.57 M 48.15 M 66.58 M 92.25 M 32.50 M
Total Debt — — — — —
Cash & Equivalents 16.21 M 22.59 M 32.15 M 24.65 M 16.51 M
Current Assets 34.58 M 53.92 M 71.88 M 96.18 M 35.33 M
Current Liabilities 5.61 M 6.59 M 6.38 M 4.52 M 3.51 M